Rung 4 · Strong
Amivantamab plus lazertinib for advanced EGFR lung cancer
Longer survival than osimertinib, with more side effects.
TreatmentWith your doctor
What studies found
In MARIPOSA (1,074 patients), first treatment with amivantamab plus lazertinib gave 3-year survival of 60% versus 51% with osimertinib alone (hazard ratio 0.75).
The catch
Serious side effects were more common: 80% versus 52% had grade 3 or worse events, and 9% versus 3% had a blood clot in the lung.
What to do
Weigh the survival gain against side effects with your oncologist.
Sources
Rung 4 of 5, Strong: At least one large randomized trial, or very large consistent studies, on this exact question. How we score
To take it to your doctor, print this page.
Step by step
For the whole picture, from prevention and screening to treatment and life after, see the lung cancer page.
Related
- Tumor gene testing before lung cancer treatmentRung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor
- Durvalumab after chemoradiation for limited-stage small cell lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Immunotherapy around surgery for non-small cell lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Targeted pills after surgery or chemoradiation for EGFR or ALK lung cancerRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor
- Tarlatamab for small cell lung cancer that returns after chemotherapyRung 4 · StrongWith your doctorRung 4 · StrongTreatmentWith your doctor